Viewing Study NCT04343092


Ignite Creation Date: 2025-12-24 @ 3:49 PM
Ignite Modification Date: 2025-12-24 @ 3:49 PM
Study NCT ID: NCT04343092
Status: COMPLETED
Last Update Posted: 2020-11-04
First Post: 2020-04-05
Is Possible Gene Therapy: False
Has Adverse Events: True

Brief Title: Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
Sponsor: University of Baghdad
Organization:

Study Overview

Official Title: Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial)
Status: COMPLETED
Status Verified Date: 2020-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Comparing the effectiveness of Ivermectin( IVM) +Hydroxychloroquin + azithromycin (AZT) group to Hydroxychloroquin (HCQ) + azithromycin (AZT)
Detailed Description: Comparing effectiveness of single dose 0.2mg/kg Ivermectin (IVM) plus hydroxychloroquine (HCQ) 400mg BID in first day then 200mg BID for 5 days plus azithromycin (AZT) 500mg in first day then 250mg for 5 days.

The comparison group was a historical control population and data collected from the current study were compared to that historical control population

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: